Answers.

• What Is Pre-Registration of Predictions?
  Pre-registration locks a prediction, its endpoint and its analysis plan before the answer exists. Why it is the only thing that separates predictive skill from hindsight in AI biology.
• How to Evaluate an AI Drug-Discovery Vendor
  The questions that separate a working model from a good deck: out-of-distribution performance, a dated prediction, a documented miss, a named context of use, and the base rate the claim has to beat.
• AAV Immunogenicity and Pre-Existing Neutralizing Antibodies
  What capsid models can predict about AAV immunogenicity, what they cannot, and why pre-existing neutralizing antibody data does not transfer between assays, cohorts or serotypes.
• Predicting Phase 3 Success: What the Evidence Says
  Phase 3 outcomes can be forecast better than chance from phase 1 and 2 features - but the published base rates, failure causes and leakage risks define exactly how far that goes.
• IO Plus TKI Combination Toxicity: The Published Profile
  What the registrational trials of pembrolizumab plus lenvatinib report about grade 3 and fatal toxicity, why population and dose trajectory move the numbers, and what real-world practice adds.
• What Is an Agentic AI Pipeline in Biomedical Research?
  An agentic pipeline is specialised AI agents with tools, an orchestrator, an audit layer and named human decision rights - what has been demonstrated, and where these systems fail.
• Capsid Tropism vs Species Translation
  Why an AAV capsid that excels in one mouse strain can fail in another and in primates - the receptor mechanism behind the field's cardinal translation trap, and how to rank candidates around it.
• How Is AI Used to Design AAV Capsids?
  AI ranks and designs AAV capsid variants from sequence data, deep mutational scans and receptor biology — and flags the species traps that break programs.
• What Is an AI-Native Research Partner?
  An AI-native partner runs the broad computational search for your program while your scientists keep every decision, with an audit trail on each claim.
• Can Agentic AI Help Validate a Drug Target?
  Agentic AI assembles and audits the evidence behind a target — genetic, mechanistic, tractability — then grades it. It does not make a target true.
• Safety Signals in Combination Oncology Trials
  Combination oncology toxicity is driven by overlapping organ risk and population fragility. Here is how safety signals are predicted, detected and checked.
• Human-in-the-Loop AI in Drug Discovery
  Human-in-the-loop AI means named decisions a model may never make alone. Here is how to define those decision rights so oversight is real, not decorative.
• What Evidence Should AI Biology Predictions Meet?
  An AI biology prediction should carry an evidence level, a pre-registered lock, an out-of-distribution number and a documented miss. Here is the standard.
• Predicting AAV Delivery Across the Blood-Brain Barrier
  AAV brain penetration is receptor-mediated transcytosis, not diffusion — so small-molecule ADME rules fail and species specificity decides translation.
• Real-World Evidence Pipelines for Biotech
  An RWE pipeline ingests trial, regulatory and literature data to measure how far real-world outcomes drift from trial results, then recalibrates the model.

Atlas Bio (atlasbiosys.com) is not Atlas Biologicals (atlasbio.com), Atlas Biotech (atlasbio.tech), the Basel-based Atlas Bio startup, or Norstella's Atlas platform. More about Atlas Bio.